JP2021534208A5 - - Google Patents

Info

Publication number
JP2021534208A5
JP2021534208A5 JP2021510013A JP2021510013A JP2021534208A5 JP 2021534208 A5 JP2021534208 A5 JP 2021534208A5 JP 2021510013 A JP2021510013 A JP 2021510013A JP 2021510013 A JP2021510013 A JP 2021510013A JP 2021534208 A5 JP2021534208 A5 JP 2021534208A5
Authority
JP
Japan
Prior art keywords
diabetes
subject
ezetimibe
composition according
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021510013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534208A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/048184 external-priority patent/WO2020041799A1/en
Publication of JP2021534208A publication Critical patent/JP2021534208A/ja
Publication of JP2021534208A5 publication Critical patent/JP2021534208A5/ja
Priority to JP2024032974A priority Critical patent/JP2024081650A/ja
Pending legal-status Critical Current

Links

JP2021510013A 2018-08-24 2019-08-26 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法 Pending JP2021534208A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024032974A JP2024081650A (ja) 2018-08-24 2024-03-05 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862722766P 2018-08-24 2018-08-24
US62/722,766 2018-08-24
US201862751404P 2018-10-26 2018-10-26
US62/751,404 2018-10-26
PCT/US2019/048184 WO2020041799A1 (en) 2018-08-24 2019-08-26 Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024032974A Division JP2024081650A (ja) 2018-08-24 2024-03-05 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法

Publications (2)

Publication Number Publication Date
JP2021534208A JP2021534208A (ja) 2021-12-09
JP2021534208A5 true JP2021534208A5 (cg-RX-API-DMAC7.html) 2022-11-09

Family

ID=69591419

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021510013A Pending JP2021534208A (ja) 2018-08-24 2019-08-26 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法
JP2024032974A Pending JP2024081650A (ja) 2018-08-24 2024-03-05 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024032974A Pending JP2024081650A (ja) 2018-08-24 2024-03-05 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法

Country Status (15)

Country Link
US (1) US20210322376A1 (cg-RX-API-DMAC7.html)
EP (1) EP3841105A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021534208A (cg-RX-API-DMAC7.html)
KR (1) KR20210079275A (cg-RX-API-DMAC7.html)
CN (1) CN113166195A (cg-RX-API-DMAC7.html)
AU (1) AU2019325705A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021003265A2 (cg-RX-API-DMAC7.html)
CA (1) CA3110346A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000444A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021003726A2 (cg-RX-API-DMAC7.html)
IL (1) IL281016A (cg-RX-API-DMAC7.html)
MX (1) MX2021002090A (cg-RX-API-DMAC7.html)
PH (1) PH12021550656A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101717WA (cg-RX-API-DMAC7.html)
WO (1) WO2020041799A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX392182B (es) 2015-03-13 2025-03-21 Esperion Therapeutics Inc Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
WO2020046836A1 (en) * 2018-08-27 2020-03-05 Esperion Therapeutics, Inc. Combination drug formulations for treating patients with cardiovascular disease and associated conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200901959A (en) * 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
CN103239449A (zh) * 2012-12-26 2013-08-14 辽宁亿灵科创生物医药科技有限公司 一种依折麦布、辛伐他汀和烟酸的复方制剂及其制备方法
MA41793A (fr) * 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
MX2019009418A (es) * 2017-02-08 2019-10-02 Esperion Therapeutics Inc Formulaciones de combinacion del triplete y metodos para tratar o reducir el riesgo de enfermedad cardiovascular.

Similar Documents

Publication Publication Date Title
JP7629049B2 (ja) 貧血治療のための組成物及び方法
CA3043284C (en) Treatment for fibrosis
KR102338085B1 (ko) 담즙울체성 질환의 치료 방법
JP2024081650A5 (cg-RX-API-DMAC7.html)
US20180125862A1 (en) Treatment for hepatic fibrosis
JP2020536866A (ja) Acc阻害剤を含む併用療法
JP2023501457A5 (cg-RX-API-DMAC7.html)
US20190175619A1 (en) Treatment of fibrosis, and inhibition of fibrosis in non-alcoholic fatty liver disease patients
JP2022542830A (ja) Eyp001を使用した改善された処置
Althubiti Tyrosine kinase targeting: a potential therapeutic strategy for diabetes
JP2024081650A (ja) 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法
WO2011150067A1 (en) Treatment of blood lipid abnormalities and other conditions
WO2025007946A1 (zh) 治疗前列腺癌的方法
CN117100748A (zh) 罗沙司他在制备治疗慢性肾脏病高脂血症药物中的应用
RU2021107420A (ru) Способы снижения риска сахарного диабета у больных, подлежащих лечению от заболеваний, связанных с высоким содержанием холестерина
US20250332176A1 (en) Treatment for fibrosis and inhibition of fibrosis
US12616698B2 (en) Methods for reducing liver fat and for treating fatty liver disorders
AU2019376907B2 (en) Treatment and inhibition of fibrosis in non-alcoholic fatty liver disease patients
US20220362263A1 (en) Treatment for fibrosis and inhibition of fibrosis
Wilkinson et al. * Real-World Experience with Inclisiran at a Large Academic Lipid Clinic
Leskovar et al. Pregnancy in Familial Chylomicronemia Syndrome: Plasmapheresis as Therapeutic Approach
WO2025036347A1 (zh) Pcsk9抑制剂用于治疗或预防胆固醇相关疾病的方法
Villeneuve et al. Treatment of Chronic Hepatitis B with Interferon: Long Term Follow‐Up
TW202517250A (zh) Lp(a)干擾劑化合物之治療用途及劑量
Modarressi Severe Hypercholesterolemia in Very-Low-Carbohydrate Diet